6-溴咪唑并[1,2-a]嘧啶-3-甲醛 | 865156-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]嘧啶
• 中文名称: 6-溴咪唑并[1,2-a]嘧啶-3-甲醛
• 英文名称: 6-bromo-imidazo[1,2-a]pyrimidine-3-carbaldehyde
• 英文别名: 6-bromoimidazo[1,2-a]pyrimidine-3-carbaldehyde；6-Bromoimidazo[1,2-a]pyrimidine-3-carbaldehyde
• CAS: 865156-67-8
• 化学式: C₇H₄BrN₃O
• 分子量: 226.032
• InChiKey: PAOLBUPEQYBJIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-溴咪唑并[1,2-a]嘧啶-3-甲醛 在 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors

  摘要：

  Since the PI3K signaling pathway is the most commonly activated in human cancers, inhibition of PI3K K is a promising approach to cancer therapy. In this study, a series of 2-methyl-5-nitrobenzeneacylhydrazones were designed and synthesized. All the new derivatives were tested by p110 alpha enzymatic and Rh30 cellular assays. Further enzyme selectivity profiling proved that 6e and 7 were potential selective P13K inhibitors. (C) 2014 Ling-Hua Meng and Wen-Hu Duan. Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. All rights reserved.

  DOI：

  10.1016/j.cclet.2014.10.016
• 作为产物：
  描述：

  2-氨基-5-溴嘧啶 、 2-溴丙二醛 在 碳酸氢钠 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 6-溴咪唑并[1,2-a]嘧啶-3-甲醛
  参考文献：
  名称：

  Imidazopyridine derivatives

  摘要：

  本发明涉及式（I）的化合物，其中Ra，Rb，Rc，Rd，Re和Rf如规范中所定义，其制备过程，包含它们的制药组合物以及它们在治疗通过磷脂酰肌醇-3-激酶（PI3K），哺乳动物雷帕霉素靶蛋白（mTOR），信号转导和转录激活因子3（STAT 3），肿瘤坏死因子-α（TNF-α），白细胞介素-6（IL-6）或其组合介导的疾病，特别是在癌症和炎症治疗中的用途。

  公开号：

  US08741932B2

文献信息

• [EN] 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION<br/>[FR] DERIVE DE 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE UTILISES EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090305A1

  公开（公告）日：2005-09-29

  The application relatés to novel alkanamides of the general formula (I) where X is -CH2- or >CH-OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl­C1-C6-alkyl; R5 is Cl-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy­ C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-Cl-C6-alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1,-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-Cl-C6-alkyl, optionally substituted aryl-­Co-C6-alkyl, optionally substituted C3-C8-cycloalkyl-Co-C6-alkyl or optionally substituted heterocydyl-Co-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  该申请涉及一般式（I）的新型烷酰胺，其中X为-CH2-或>CH-OH；（A）R1例如是一个可选择取代的杂环基团或一个可选择取代的多环不饱和碳氢基团，其中X为羟甲基；R2为C1-C6-烷基或C3-C6-环烷基；R3各自独立地为H、C1-C6-烷基、C1-6-烷氧羰基或C1-C6-烷酰基；R4为C1-C6-烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基-C1-C6-烷基；R5为Cl-C6-烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-烷酰氧基-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-Cl-C6-烷基、C1-C6-烷酰胺基-C1-C6-烷基、HO(O)C-C1-C6-烷基、C1-C6-烷基-O-(O)C-C1-C6-烷基、H2N-C(O)-C1-C6-烷基、C1-C6-烷基-HN-C(O)-C1-C6-烷基、（C1,-C6-烷基）2N-C(O)-C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代Cl-C6-烷基、可选择取代的芳基-Co-C6-烷基、可选择取代的C3-C8-环烷基-Co-C6-烷基或可选择取代的杂环基-Co-C6-烷基；以及它们的制备方法和将这些化合物用作药物的用途，特别是作为肾素抑制剂治疗高血压。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• [EN] IMIDAZOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011055320A1

  公开（公告）日：2011-05-12

  The present invention relates to compounds of formula (I), wherein Ra, Rb, Rc, Rd, Re and Rf are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PBK), mammalian target of rapamycin (mTOR), Signal transducer and activator of transcription 3 (STAT 3), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) or a combination thereof particularly in the treatment of cancer and inflammation.

  本发明涉及式(I)的化合物，其中Ra、Rb、Rc、Rd、Re和Rf如规范中所定义，其制备方法，含有它们的药物组合物以及它们在磷脂酰肌醇-3-激酶（PI3K）、哺乳动物雷帕霉素靶蛋白酶（mTOR）、信号转导与转录激活因子3（STAT3）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）或二者组合介导的疾病治疗中的用途，特别是在癌症和炎症治疗中。
• Organic Compounds
  申请人：Herold Peter

  公开号：US20080058320A1

  公开（公告）日：2008-03-06

  The invention relates to novel amino alcohols of the general formula (I) where X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型的氨基醇，其通式为(I)，其中X，R1，R2，R3，R4，R5和R6分别如详细描述中所定义，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension
  申请人：Herold Peter

  公开号：US20080280895A1

  公开（公告）日：2008-11-13

  The application relates to novel alkanamides of the general formula (I) where X is —CH 2 — or >CH—OH; (A) R 1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R 2 is C 1 -C 6 -alkyl or C 3 -C 6 -cydoalkyl; R 3 are each independently H, C 1 -C 6 -alkyl, C 1-6 -alkoxycarbonyl or C 1 -C 6 -alkanoyl; R 4 is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -alkenyl or unsubstituted or substituted arylC 1 -C 6 -alkyl; R 5 is C 1 -C 6 -alkyl, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoyloxy C 1 -C 6 -alkyl, C 1 -C 6 -aminoalkyl, C 1 -C 6 -alkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -dialkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoylamido-C 1 -C 6 -alkyl, HO(O)C—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-O—(O)C—C 1 -C 6 -alkyl, H 2 N—C(O)—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-HN—C(O)—C 1 -C 6 -alkyl, (C 1 , —C 6 -alkyl) 2 N—C(O)—C 1 -C 6 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, cyano-C 1 -C 6 -alkyl, halo-C 1 -C 6 -alkyl, optionally substituted aryl-C o -C 6 -alkyl, optionally substituted C 3 -C 8 -cycloalkyl-C o -C 6 -alkyl or optionally substituted heterocydyl-C o -C 6 -alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  该申请涉及到通式（I）的新型烷基酰胺，其中X为—CH2—或>CH—OH；（A）R1为例如可选择取代的杂环基基团或可选择取代的多环不饱和碳氢基团，其中X为羟甲基；R2为C1-C6-烷基或C3-C6-环烷基；R3各自独立地为H、C1-C6-烷基、C1-6-烷氧羰基或C1-C6-酰基；R4为C1-C6-烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基C1-C6-烷基；R5为C1-C6-烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-酰氧-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-C1-C6-烷基、C1-C6-酰胺基-C1-C6-烷基、HO(O)C—C1-C6-烷基、C1-C6-烷基-O—(O)C—C1-C6-烷基、H2N—C(O)—C1-C6-烷基、C1-C6-烷基-HN—C(O)—C1-C6-烷基、（C1，—C6-烷基）2N—C(O)—C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代-C1-C6-烷基、可选择取代的芳基-Co-C6-烷基、可选择取代的C3-C8-环烷基-Co-C6-烷基或可选择取代的杂环基-Co-C6-烷基；以及它们的制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂治疗高血压。